Beleodaq 500 mg
Belinostat is a drug utilized for the treatment of backslid or unmanageable fringe T-cell lymphoma (PTCL).
Belinostat is a histone deacetylase (HDAC) inhibitor demonstrated for the treatment of patients with backslid or recalcitrant fringe T-cell lymphoma (PTCL), which indicates special cytotoxicity towards tumour cells contrasted with ordinary cells1.
A fringe T-cell lymphoma is a gathering of T-cell lymphomas, platelet tumours that influence T-cells, that grow far from the thymus.
- Liver problems
- Serious infections
- Low blood cell counts
- Nausea, vomiting, and diarrhoea